FibroBiologics Finalizes $0.5 Million Private Placement with Its Chief Scientific Officer

FibroBiologics Closes $0.5 Million Private Placement

FibroBiologics, Inc. (Nasdaq: FBLG), a prominent clinical-stage biotechnology company based in Houston, has successfully completed a private placement valued at $0.5 million. This placement, finalized on September 15, 2026, involved shares purchased by Hamid Khoja, Ph.D., who serves as the company's Chief Scientific Officer. The move underscores the commitment of FibroBiologics to advance its innovative therapeutic solutions aimed at treating chronic diseases.

The private placement consisted of 298,508 shares of common stock, along with corresponding warrants also allowing the purchase of the same number of shares. Each combined unit was priced at $1.675—reflecting a strategic approach based on the company's market performance and the closing bid price of $1.55 from the previous trading day.

This latest funding initiative has generated gross proceeds that will be utilized for various corporate needs, including operational costs and further investment in R&D. CEO Pete O'Heeron expressed his enthusiasm regarding Dr. Khoja's deeper investment in the company, noting it's a testament to the strength of their scientific platform and the underlying market potential. O’Heeron reiterated that their focus on advancing the clinical pipeline is unwavering, especially with projects like CYWC628 making significant progress.

Dr. Khoja voiced his unwavering belief in the transformative potential of the fibroblast technology that FibroBiologics is pioneering. He emphasized that the ongoing breakthroughs made by their devoted team not only affirm his trust in their work but also highlight the promising therapeutic capabilities these cells possess for the treatment of various chronic ailments.

FibroBiologics stands at the forefront of biotechnological innovation, holding over 270 patents either issued or in various stages of processing globally. The company concentrates on leveraging fibroblasts and their derived materials to design treatments for chronic conditions, with a strong focus on areas such as wound healing, multiple sclerosis, and orthopedic injuries.

Furthermore, the securities involved in this private placement were offered under the Regulation D and the Securities Act of 1933, allowing for a private sale without the need for SEC registration. This ensures that the company can raise capital efficiently while maintaining compliance with applicable regulations.

Despite the promising outlook, the company acknowledges the inherent risks involved in navigating the biotechnology sector, which include liquidity challenges and variables affecting research and development outcomes. Therefore, investors are advised to consider these factors carefully when evaluating the company's future performance.

As FibroBiologics continues to expand its clinical trials across various health sectors, it aims not only to innovate solutions that could significantly enhance patient care but also to solidify its position in the rapidly growing biotechnology landscape. For further inquiries, interested parties are encouraged to visit their official website or contact their public relations team for more detailed information.

In conclusion, the successful closure of this private placement marks a pivotal point in FibroBiologics' journey. It reflects not just an infusion of funds, but also a shared vision among its leadership for pioneering groundbreaking therapies that could redefine treatment paradigms in medicine.